Petrucci, Maria Teresa

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 2,210

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 1,899

Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., et al. (2014) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 778

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 698

ATM-ATR–dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

Soriani, A., Zingoni, A., Cerboni, C., Iannitto, M. L., Ricciardi, M. R., Di Gialleonardo, V., Cippitelli, M., Fionda, C., Petrucci, M. T., Guarini, A., et al. (2009) · Blood

Immune Cell Function and InteractionMultiple Myeloma Research and Treatments

Cited by 460

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 423

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma

Palumbo, A., Gay, F., Cavallo, F., Di Raimondo, F., Larocca, A., Hardan, I., Nagler, A., Petrucci, M. T., Hajek, R., Pezzatti, S., et al. (2015) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 150

Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells.

De Felice, L., Tatarelli, C., Mascolo, M. G., Gregorj, C., Agostini, F., Fiorini, R., Gelmetti, V., Pascale, S., Padula, F., Petrucci, M. T., et al. (2005) · Cancer Research

Hematopoietic Stem Cell TransplantationMesenchymal stem cell research

Cited by 149

Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).

Attal, M., Palumbo, A., Holstein, S. A., Lauwers-Cances, V., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Anderson, K. C., Caillot, D., et al. (2016) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 63

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies

Bringhen, S., Mina, R., Petrucci, M. T., Gaidano, G., Ballanti, S., Musto, P., Offidani, M., Spada, S., Benevolo, G., Ponticelli, E., et al. (2019) · Haematologica

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 25

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Bruzzese, A., Derudas, D., Galli, M., Martino, E. A., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Farina, G., et al. (2022) · Hematological Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 17

P945: REAL-WORLD CLINICAL OUTCOMES AMONG TRIPLE-CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS IN US AND EUROPE: A PREAMBLE REGISTRY STUDY

Ramasamy, K., Goldschmidt, H., Moreau, P., Petrucci, M.-T., Kuter, D., Durie, B., Cella, D., Dhanda, D., Gu, J., Amin, S., et al. (2023) · HemaSphere

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 3